Ostrowski R.A.,Immunology and Rheumatology and |
Ostrowski R.A.,Loyola University |
Bussey M.R.,Immunology and Rheumatology and |
Tehrani R.,Immunology and Rheumatology and |
Jay W.,Loyola University Chicago
Neuro-Ophthalmology | Year: 2014
Giant cell arteritis (GCA), a vasculitis of the medium and large arteries, is traditionally managed with glucocorticoids. However, the side effects of chronic glucocorticoid use and the occurrence of refractory cases warrant the consideration of steroid-sparing agents, including biologic agents. Interleukin-6 (IL-6) inhibition shows the most promise as biologic therapy for refractory cases of GCA, but data to support the use of other existing biologic agents are currently lacking. A better understanding of the pathogenesis of GCA as well as clinical trials investigating both existing and emerging biologic agents is needed to expand therapeutic options for the treatment of GCA. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.